Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Epilepsy | Unmet Need | Lennox-Gastaut Syndrome | US/EU | 2022

Login to access report north_east
Contact sales account_box

Lennox-Gastaut syndrome (LGS) is a severe pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities. Only a handful of antiepileptic drugs (AEDs), including Epidiolex (cannabidiol), rufinamide, clobazam, and, most recently, Fintepla (fenfluramine), are approved for the adjunctive treatment of LGS, but certain other AEDs (e.g., levetiracetam) remain a frequent off-label choice for LGS treatment. Moreover, most patients do not achieve complete seizure control with currently available AEDs, even when prescribed concomitantly. Understanding the drivers of clinical decision-making in LGS, prescribers’ perception of current treatment options, and areas of remaining unmet need will help drug developers optimize the positioning and differentiation of new products.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in LGS?
  • What attributes drive decision-making in LGS, which have limited impact, and which are hidden opportunities?
  • How do key agents (e.g., Epidiolex, clobazam, rufinamide) perform on queried attributes?
  • What are the prevailing areas of unmet need and opportunity in LGS?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and prices are acceptable to neurologists for a hypothetical new LGS drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in April 2022.

Key companies: GW Pharmaceuticals, Zogenix, Eisai, UCB Pharmaceuticals

Key drugs: Epidiolex / Epidyolex, Fintepla, rufinamide, clonazepam, lamotrigine, topiramate, levetiracetam

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east